<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Chapter 19 Sterile Pharmaceutical Compounding | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.34.19/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.34.19/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|34|19|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="19"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|34|19" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.34.19"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Chapter 19 Sterile Pharmaceutical Compounding | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.34.19/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.34.19/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|34" data-search-heading="">
                  <a href="/us/md/exec/comar/10.34" title="Subtitle 34 BOARD OF PHARMACY">Subtitle 34 BOARD OF PHARMACY</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|34|19" data-search-heading="">
                  <span title="Chapter 19 Sterile Pharmaceutical Compounding">Chapter 19 Sterile Pharmaceutical Compounding</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|34|19">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.34.19">Chapter 19 Sterile Pharmaceutical Compounding</h1>
                <section class="line-group annotations">
                  <h2>Administrative History</h2>
                  <p>Effective date: February 19, 1990 (17:3 Md. R. 299)</p>
                  <p>Regulation .04B amended effective July 20, 1992 (19:14 Md. R. 1284)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.05" title=".05 General Requirements.">Regulation .05</a> amended effective July 20, 1992 (19:14 Md. R. 1284)</p>
                  <p>——————</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.01" title=".01 Scope.">.01</a> — <a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.06" title=".06 Special Handling, Packaging, Labeling, and Beyond Use Dating.">.06</a> repealed and new Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.01" title=".01 Scope.">.01</a> — <a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.16" title=".16 Reference Library.">.16</a> adopted effective September 10, 2007 (34:18 Md. R. 1580)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.01" title=".01 Scope.">Regulation .01</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.02" title=".02 Incorporation by Reference.">Regulation .02</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.03#B" title="">Regulation .03B</a> amended effective February 23, 2009 (36:4 Md. R. 354); February 1, 2016 (43:2 Md. R. 127)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.05#A" title="">Regulation .05A</a> amended effective February 1, 2016 (43:2 Md. R. 127)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.06#A" title="">Regulation .06A</a> amended effective February 1, 2016 (43:2 Md. R. 127)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.06#A" title="">Regulation .06A</a>, D amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.07#A" title="">Regulation .07A</a> amended effective February 1, 2016 (43:2 Md. R. 127)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.09" title=".09 Minimum Facility Requirements.">Regulation .09</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.09#A" title="">Regulation .09A</a> amended effective February 1, 2016 (43:2 Md. R. 127)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.10" title=".10 Minimum Requirements for Equipment.">Regulation .10</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.11" title=".11 Minimum Requirements for Supplies.">Regulation .11</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.13" title=".13 Attire.">Regulation .13</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.14#E" title="">Regulation .14E</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.15#C" title="">Regulation .15C</a>, E amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.16#A" title="">Regulation .16A</a> amended effective February 23, 2009 (36:4 Md. R. 354)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.17" title=".17 Minimum Requirements for Inspections.">Regulation .17</a> adopted effective February 1, 2016 (43:2 Md. R. 127)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.18" title=".18 Reporting Requirements Pharmacies.">Regulation .18</a> adopted effective February 1, 2016 (43:2 Md. R. 127)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19.19" title=".19 Office Use.">Regulation .19</a> adopted effective February 1, 2016 (43:2 Md. R. 127)</p>
                  <h2>Authority</h2>
                  <p>Health Occupations Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-205" title="">12-205</a>, <a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-403" title="">12-403</a>, <a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-503" title="">12-503</a>, <a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-505" title="">12-505</a>, <a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-6" title="">12-6</a>C-<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=01" title="">01</a>, and <a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-6" title="">12-6</a>C-03, Annotated Code of Maryland</p>
                </section>
                <h2 id="/us/md/exec/comar/10.34.19.01" data-order="|10|34|19|.01|" data-ref-path="10|34|19|.01" class="h__section">.01 Scope.</h2>
                <p>This chapter applies to a licensed pharmacy in Maryland engaging in:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.01#A">A.</span> Compounding or mixing sterile prescription solutions or suspensions to be administered parenterally or by irrigation, inhalation, or intraocular routes; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.01#B">B.</span> Compounding of radiopharmaceuticals, except where U.S. Pharmacopeia (USP) General Chapter 797 Pharmaceutical Compounding — Sterile Preparations addresses radiopharmaceuticals, U.S. Pharmacopeia (USP) Chapter 821 Radioactivity, and U.S. Pharmacopeia (USP) Chapter 823 Radiopharmaceuticals for Positron Emission Tomography — Compounding would apply.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.02" data-order="|10|34|19|.02|" data-ref-path="10|34|19|.02" class="h__section">.02 Incorporation by Reference.</h2>
                <p>In this chapter, the following documents are incorporated by reference:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.02#A">A.</span> U.S. Pharmacopeia (USP) General Chapter 797 Pharmaceutical Compounding — Sterile Preparations (USP 797 Standards), which has been incorporated by reference in 21 U.S.C. §351(b) (as amended).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.02#B">B.</span> U.S. Pharmacopeia (USP) General Chapter 795 Pharmaceutical Compounding — Non-Sterile Preparations (USP 795 Standards), which has been incorporated by reference in 21 U.S.C. §351(b) (as amended).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.02#C">C.</span> U.S. Pharmacopeia (USP) Chapter 821 Radioactivity, which has been incorporated by reference in 21 U.S.C. §351(b) (as amended).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.02#D">D.</span> U.S. Pharmacopeia (USP) Chapter 823 Radiopharmaceuticals for Positron Emission Tomography — Compounding, which has been incorporated by reference in 21 U.S.C. §351(b) (as amended).</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.03" data-order="|10|34|19|.03|" data-ref-path="10|34|19|.03" class="h__section">.03 Definitions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(1)">(1)</span> “Adverse event” means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(1)(a)">(a)</span> Any adverse patient outcome related to the sterile compounding process; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(1)(b)">(b)</span> Evidence of environmental contamination, including microbial contamination above the threshold set forth in USP 797 Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(2)">(2)</span> "Antineoplastic" means an agent that prevents the development, growth, or proliferation of malignant cells.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(3)">(3)</span> "Anteroom" means the area, room, or rooms where personnel perform hand hygiene and garbing immediately adjacent to the designated clean room where the compounding of sterile preparations is performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(4)">(4)</span> Batch.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(4)(a)">(a)</span> "Batch" means a preparation compounded in advance of receipt of a prescription, or a preparation compounded in a supply that will be used on more than one dispensing to a patient or patients or any preparation compounded in excess of the filling of an individual prescription.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(4)(b)">(b)</span> "Batch" includes a limited quantity of identical preparations compounded in a single, discrete process, by the same individuals, carried out during one limited time period.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(5)">(5)</span> "Biological safety cabinet" means a containment unit:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(5)(a)">(a)</span> Suitable for work involving agents that pose higher risk of exposure to operators during compounding; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(5)(b)">(b)</span> Used when there is a need for protection of the preparation, personnel, and environment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(6)">(6)</span> “Clean room” means a room with an International Standards Organization (ISO) Class 5 environment or an ISO Class 7 environment that meets USP 797 Standards, inside which compounding occurs within an ISO Class 5 engineering control device such as a laminar airflow workstation or a biological safety cabinet.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(7)">(7)</span> "Closed system vial transfer device (CSTD)" means a closed system drug transfer device that mechanically, not by means of vents or filters, prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug aerosols or vapors into the environment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(8)">(8)</span> "Compounded sterile preparation" means sterile medication preparations, such as intravenous, epidural, and intraocular medications, compounded in the pharmacy using currently accepted aseptic compounding techniques under acceptable compounding conditions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(9)">(9)</span> “Compounding” means the preparation, mixing, assembling, packaging, or labeling of a drug:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(9)(a)">(a)</span> As the result of a practitioner’s prescription drug order or initiative based on the practitioner/patient relationship in the course of professional practice;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(9)(b)">(b)</span> For the purpose of, or incidental to, research, teaching, or chemical analysis and not for the sale or dispensing of the drug or device; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(9)(c)">(c)</span> In anticipation of a prescription drug order based on routine, regularly observed prescribing patterns.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(10)">(10)</span> "Compounding aseptic isolator" means an enclosed positive or negative pressure environment especially designed for sterile preparation compounding that maintains a physical barrier between the workspace and the operator.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(11)">(11)</span> "Controlled environment" means a designated area for compounding sterile preparations that consists of a clean room and an anteroom.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(12)">(12)</span> "Cytotoxic" means drug entities that are damaging or debilitating to cells, tissues, or organs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(13)">(13)</span> “Designee” means a public agency or private entity trained in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(13)(a)">(a)</span> USP 797 Standards;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(13)(b)">(b)</span> FDA good manufacturing practices approved by the Board to conduct inspections of nonresident pharmacies that perform sterile compounding; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(13)(c)">(c)</span> Both §B(13)(a) and (b) of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(14)">(14)</span> "Laminar air flow workstation" means an ISO Class 5 ("Class 100") laminar airflow hood inside which sterile compounding occurs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(15)">(15)</span> "Media fill verification" means a process of practical examination to verify the aseptic technique of personnel or an aseptic process by manual manipulation of microbiological growth media which simulates compounding processes and techniques used in actual compounding procedures.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(16)">(16)</span> "Parenteral" means routes of drug administration or fluid administration other than via the gastrointestinal tract.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(17)">(17)</span> "Pharmacist" means an individual who is licensed to practice pharmacy regardless of the location where the activities of practice are performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(18)">(18)</span> "Pharmacy" means an establishment in which prescription or nonprescription drugs or devices are compounded, dispensed, or distributed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(19)">(19)</span> "Pyrogen testing" means an analysis of sterile preparations for the presence of cell material from microbiological organisms in sufficient quantity to elicit a febrile reaction.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(20)">(20)</span> “Risk level” means a risk level of low, medium, or high as defined in USP 797 Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(21)">(21)</span> "Sterile" means free from living microorganisms or any other contaminants.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(22)">(22)</span> “Sterile compounding” means compounding of biologics, diagnostics, drugs, nutrients, and radiopharmaceuticals that, under USP 797 Standards, are prepared using aseptic techniques.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(23)">(23)</span> "Total parenteral nutrition" means providing caloric needs by the parenteral route for a patient who is unable to ingest sufficient calories.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(24)">(24)</span> "USP 795 Standards" means standards set forth in the US Pharmacopeia (USP) General Chapter 795 Pharmaceutical Compounding — Non-Sterile Preparations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.03#B(25)">(25)</span> "USP 797 Standards" means standards set forth in the U.S. Pharmacopeia (USP) General Chapter 797 Pharmaceutical Compounding — Sterile Preparations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.04" data-order="|10|34|19|.04|" data-ref-path="10|34|19|.04" class="h__section">.04 Pharmacy Environment.</h2>
                <p>The compounding, preparation, and dispensing of compounded sterile preparations shall be accomplished in a pharmacy environment subject to State and federal laws, regulations, and standards.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.05" data-order="|10|34|19|.05|" data-ref-path="10|34|19|.05" class="h__section">.05 General Requirements.</h2>
                <p>A licensed pharmacist who has appropriate practical and didactic training in compounding sterile preparations, clean room technology, laminar flow technology, quality assurance techniques, and clinical application of intravenous drug therapy shall control and supervise the section of the pharmacy that prepares compounded sterile preparations and is responsible for, at a minimum, the following:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.05#A">A.</span> Preparation of compounded sterile preparations within the pharmacy or decentralized pharmacy;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.05#B">B.</span> Storage of materials pertinent to the preparation of compounded sterile preparations, including drugs, chemicals, and biologicals, and the establishment of specifications for procurement of the materials;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.05#C">C.</span> Labeling of containers of compounded sterile preparations compounded within the pharmacy;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.05#D">D.</span> Recording of transactions of the pharmacy as may be applicable to State and federal laws and regulations, as may be necessary to maintain accurate control over, and accountability for, pharmaceutical materials; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.05#E">E.</span> Ensuring that licensed pharmacists meeting the requirements of <a class="internal-link " href="/us/md/exec/comar/10.34.19.05#A" title="">§A of this regulation</a>, or registered pharmacy technicians under direct supervision of a licensed pharmacist meeting the requirements of <a class="internal-link " href="/us/md/exec/comar/10.34.19.05#A" title="">§A of this regulation</a>, prepare, compound, and dispense compounded sterile preparations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.06" data-order="|10|34|19|.06|" data-ref-path="10|34|19|.06" class="h__section">.06 Special Handling, Packaging, Labeling, and Beyond Use Dating.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#A">A.</span> The pharmacy shall make available special handling and packaging materials to maintain container integrity and drug stability of the prepared prescription orders, including antineoplastic or other hazardous sterile preparations, during handling and administration to the patient including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#A(1)">(1)</span> A reasonable effort to provide tamper-evident packaging if appropriate to setting;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#A(2)">(2)</span> Proper in-transit storage consistent with preparation labeling; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#A(3)">(3)</span> Delivery to the patient within a reasonable time.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B">B.</span> The dispensed container for any compounded sterile preparation shall include labeling according to Maryland law and regulations, in addition to the following information that is required by federal law:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(1)">(1)</span> The date of preparation unless otherwise readily retrievable from prescription records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(2)">(2)</span> Time prepared, if applicable;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(3)">(3)</span> The pertinent requirements for proper storage;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(4)">(4)</span> The name of the prescriber, unless in an inpatient hospital setting;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(5)">(5)</span> The name of the patient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(6)">(6)</span> Directions for use;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(7)">(7)</span> The name of the base solution for infusion preparations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(8)">(8)</span> The name and concentration or amount of active drugs contained in the final sterile preparation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(9)">(9)</span> The name or identifying initials of the pharmacist who checked or prepared the compounded sterile preparation unless otherwise readily retrievable from prescription records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(10)">(10)</span> The name, address, and telephone number of the pharmacy unless in an inpatient hospital facility;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(11)">(11)</span> The beyond-use/expiration dating and time of the compounded sterile preparation, and if no time is stated, the time is presumed to be at 11:59 p.m. of the stated beyond use date;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(12)">(12)</span> Any ancillary and cautionary instructions as needed; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#B(13)">(13)</span> A pertinent warning consistent with applicable federal and State law that cytotoxic preparations are biohazardous, when applicable.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#C">C.</span> A pharmacy compounding sterile infusion preparations shall provide a 24-hour telephone number to allow its patients or other health care providers who may be administering its prescriptions to contact its pharmacists.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.06#D">D.</span> Expiration or Beyond-Use Dating. In the absence of direct testing evidence, as detailed in the Stability Criteria and Beyond Use Dating section of USP 795 Standards, the pharmacist shall use "beyond-use dating" as determined by USP 797 Standards and reference materials as cited in <a class="internal-link " href="/us/md/exec/comar/10.34.19.16" title=".16 Reference Library.">Regulation .16 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.07" data-order="|10|34|19|.07|" data-ref-path="10|34|19|.07" class="h__section">.07 Record-Keeping Requirements.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A">A.</span> Patient Prescription Records.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A(1)">(1)</span> The pharmacy shall maintain records of patient prescriptions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A(2)">(2)</span> Patient prescription records shall contain:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A(2)(a)">(a)</span> Available medical information consistent with prevailing pharmacy standards; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A(2)(b)">(b)</span> The complete record of the formulations of the solutions that were compounded.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A(3)">(3)</span> The pharmacy shall keep completed patient prescription records in a retrievable manner for at least 5 years, either:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A(3)(a)">(a)</span> At the inspection site; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#A(3)(b)">(b)</span> So as to be immediately retrievable by computer or other electronic means.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B">B.</span> Compounded Sterile Preparations Records.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)">(1)</span> For a pharmacy preparing compounded sterile preparations, the following records shall be maintained for at least 5 years:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)(a)">(a)</span> The training and competency evaluation of employees in sterile preparation procedures;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)(b)">(b)</span> Refrigerator and freezer temperatures;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)(c)">(c)</span> Certification of the sterile compounding environment, including ISO 5 workstations and the clean and anterooms;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)(d)">(d)</span> Other facility quality control logs specific to the pharmacy's policies and procedures, for example, cleaning logs for facilities and equipment;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)(e)">(e)</span> Records documenting inspection for expired or recalled pharmaceutical preparations or raw ingredients;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)(f)">(f)</span> Preparation records including compounding work sheets, and records of the registered pharmacy technicians' checking/sign-off process; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(1)(g)">(g)</span> Preparation records including compounding work sheets and records of the pharmacists' checking/sign-off process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(2)">(2)</span> In addition to the records requirement in <a class="internal-link " href="/us/md/exec/comar/10.34.19.07#B(1)" title="">§B(1) of this regulation</a>, for batch compounded sterile preparations, a pharmacy compounding sterile batch preparations for future use shall have records indicating the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(2)(a)">(a)</span> Drug and ingredient names;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(2)(b)">(b)</span> Lot numbers;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(2)(c)">(c)</span> Expiration dates;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(2)(d)">(d)</span> Drug/diluent amounts; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(2)(e)">(e)</span> Date on which the compounded sterile batch preparations were prepared.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.07#B(3)">(3)</span> A pharmacy shall maintain records of media fill verification results for 5 years.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.08" data-order="|10|34|19|.08|" data-ref-path="10|34|19|.08" class="h__section">.08 Batch Preparation.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.08#A">A.</span> A pharmacist may prepare batched sterile preparations for future use in limited quantities supported by prior valid prescriptions or physician orders before receiving a valid written prescription or medication order.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.08#B">B.</span> Batch preparation of specific compounded sterile preparations is acceptable if the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.08#B(1)">(1)</span> Pharmacist can document a history of valid prescriptions or physician orders that have been generated solely within an established professional prescriber-patient-pharmacist relationship; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.08#B(2)">(2)</span> Pharmacy maintains the prescription on file for such preparations dispensed.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.09" data-order="|10|34|19|.09|" data-ref-path="10|34|19|.09" class="h__section">.09 Minimum Facility Requirements.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A">A.</span> Controlled Environment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A(1)">(1)</span> The pharmacy shall have a controlled environment that meets USP 797 Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A(2)">(2)</span> A pharmacist shall ensure that the controlled environment is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A(2)(a)">(a)</span> Accessible only to designated personnel; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A(2)(b)">(b)</span> Used only for the preparation of compounded sterile preparations, or such other tasks that require a controlled environment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A(3)">(3)</span> The permit holder shall ensure that the controlled environment is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A(3)(a)">(a)</span> Structurally isolated from other areas within the pharmacy by means of restricted entry or access; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#A(3)(b)">(b)</span> Air conditioned to maintain a temperature of the controlled environment according to USP 797 standards.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B">B.</span> Controlled Environment — Clean Room. The permit holder shall ensure that the clean room in the controlled environment:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(1)">(1)</span> Meets USP 797 Standards for design and USP 797 performance criteria quality standards for clean rooms;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(2)">(2)</span> Contains no sinks or floor drains;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(3)">(3)</span> Contains work surfaces constructed of smooth, impervious materials, such as stainless steel or molded plastic, so that the work surfaces may be readily cleaned and sanitized;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(4)">(4)</span> If cytotoxic agents are routinely used in compounding preparations, contains room or rooms equipped with special pressurization requirements consistent with USP 797 Standards and the National Institute for Occupational Safety and Health (NIOSH) standards;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(5)">(5)</span> Has in place appropriate environmental engineering control devices capable of maintaining USP 797 air-quality standards during normal compounding activity; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(6)">(6)</span> Contains the following equipment:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(6)(a)">(a)</span> A laminar airflow workstation or other suitable International Standards Organization (ISO) Class 5 compounding environment;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(6)(b)">(b)</span> Waste containers that are approved by Occupational Safety and Health Administration (OSHA) for used needles and syringes, and for chemotherapy waste; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#B(6)(c)">(c)</span> Ancillary supplies required for proper compounding.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#C">C.</span> Controlled Environment — Anteroom. The permit holder shall ensure that the anteroom in the controlled environment:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#C(1)">(1)</span> Meets USP 797 Standards for design and USP 797 performance criteria quality standards for anterooms; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#C(2)">(2)</span> Contains the following equipment:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#C(2)(a)">(a)</span> A sink with hot and cold running water;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#C(2)(b)">(b)</span> Waste containers for personal protective equipment;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#C(2)(c)">(c)</span> An eyewash station or sink design suitable for flushing an eye injury; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#C(2)(d)">(d)</span> A hazardous waste spill kit, if applicable.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#D">D.</span> The requirements specified in §§B(1) and C(1) of this regulation are not applicable if a compounding aseptic isolator is used to compound sterile preparations in accordance with the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#D(1)">(1)</span> Compounding aseptic isolator conditions set forth in USP 797 Standards; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.09#D(2)">(2)</span> Isolator vendor or manufacturer specifications.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.10" data-order="|10|34|19|.10|" data-ref-path="10|34|19|.10" class="h__section">.10 Minimum Requirements for Equipment.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A">A.</span> The permit holder shall provide at least the following equipment that is maintained in working order:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(1)">(1)</span> Adequate refrigerator and freezer space (if applicable);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(2)">(2)</span> A sink and wash area in the anteroom;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(3)">(3)</span> Appropriate waste containers for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(3)(a)">(a)</span> Used needles and syringes; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(3)(b)">(b)</span> Cytotoxic waste including disposable apparel used in its preparation, if applicable;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(4)">(4)</span> Laminar air flow workstation or compounding aseptic isolator that meets USP 797 Standards, dedicated for products other than antineoplastics;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(5)">(5)</span> If applicable to types of preparations compounded, biological safety cabinet, or compounding aseptic isolator that meets USP 797 Standards, dedicated for use with antineoplastics or other hazardous sterile preparations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(6)">(6)</span> Appropriate filters and filtration equipment; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#A(7)">(7)</span> A device for light/dark field examination.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#B">B.</span> If used, the permit holder shall provide the following equipment that is maintained in working order, calibrated, or certified where appropriate:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#B(1)">(1)</span> Autoclave;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#B(2)">(2)</span> Automated compounding devices (for example, total parenteral nutrition compounding pumps);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#B(3)">(3)</span> Electronic balance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#B(4)">(4)</span> Convection oven;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#B(5)">(5)</span> Thermometers or other temperature device; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.10#B(6)">(6)</span> Incubator.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.11" data-order="|10|34|19|.11|" data-ref-path="10|34|19|.11" class="h__section">.11 Minimum Requirements for Supplies.</h2>
                <p>A pharmacy engaging in compounding sterile preparations shall maintain adequate stock levels of the following supplies according to USP 797 Standards, including but not limited to:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A">A.</span> Personal protective equipment:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A(1)">(1)</span> Sterile gloves;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A(2)">(2)</span> Masks;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A(3)">(3)</span> Non-shedding gowns;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A(4)">(4)</span> Shoe covers;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A(5)">(5)</span> Hair covers;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A(6)">(6)</span> Beard covers; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#A(7)">(7)</span> Other personal protective equipment;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#B">B.</span> Disposable syringes and needles in necessary sizes;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#C">C.</span> Disinfectant cleaning agents as specified in USP 797 Standards, including 70 percent sterile isopropyl alcohol;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#D">D.</span> Disposable lint free towels;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#E">E.</span> Hand washing materials, including antimicrobial skin cleanser;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#F">F.</span> Adequate equipment and materials for antineoplastic or cytotoxic agent spills;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#G">G.</span> Supplies necessary for the aseptic preparation of compounded sterile preparations; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.11#H">H.</span> Closed system vial transfer devices (CSTD), as required for cytotoxic compounding, if applicable.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.12" data-order="|10|34|19|.12|" data-ref-path="10|34|19|.12" class="h__section">.12 Minimum Requirements for Policies and Procedures.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#A">A.</span> The permit holder shall ensure that the pharmacist or the pharmacist's designee shall maintain a policy and procedure manual, reviewed annually, that sets forth in detail the permit holder's standard operating procedures with regard to compounding sterile preparations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#B">B.</span> The permit holder shall insure that the policy and procedure manual that sets forth the standard operating procedures with regard to compounding sterile preparations is implemented and adhered to.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C">C.</span> The policy and procedure manual shall include policies and procedures governing the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(1)">(1)</span> A risk-management program which includes documentation of outcomes including, but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(1)(a)">(a)</span> An incident reporting system;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(1)(b)">(b)</span> An adverse drug reaction reporting system; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(1)(c)">(c)</span> A preparation contamination reporting system;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(2)">(2)</span> Security measures ensuring that the premises where sterile compounded preparations are stored and prepared are secured, to prevent access by unauthorized personnel;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(3)">(3)</span> Equipment including, but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(3)(a)">(a)</span> Procedures for use;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(3)(b)">(b)</span> Documentation of appropriate certifications; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(3)(c)">(c)</span> Documentation of appropriate calibration and preventive maintenance if applicable;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(4)">(4)</span> Sanitation standards and procedures including monitoring for bacterial microorganisms to demonstrate effectiveness of cleaning activities;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(5)">(5)</span> Reference materials as set forth in <a class="internal-link " href="/us/md/exec/comar/10.34.19.16" title=".16 Reference Library.">Regulation .16 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)">(6)</span> Information concerning drug:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(a)">(a)</span> Preparation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(b)">(b)</span> Storage and handling;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(c)">(c)</span> Dispensing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(d)">(d)</span> Labeling;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(e)">(e)</span> Beyond-use/expiration dating;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(f)">(f)</span> Delivery;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(g)">(g)</span> Destruction;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(h)">(h)</span> Recalls; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(6)(i)">(i)</span> Returns;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(7)">(7)</span> Patient record keeping as set forth in <a class="internal-link " href="/us/md/exec/comar/10.34.19.07" title=".07 Record-Keeping Requirements.">Regulation .07 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(8)">(8)</span> Handling, dispensing, and documentation of investigational drugs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(9)">(9)</span> A quality assurance program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(10)">(10)</span> Verification of training and competency guidelines;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(11)">(11)</span> Compounding process media fill verification procedures;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(12)">(12)</span> Description of appropriate garb;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(13)">(13)</span> Conduct guidelines for personnel in the controlled areas;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(14)">(14)</span> Personnel responsibilities;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(15)">(15)</span> Patient education, if appropriate;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(16)">(16)</span> Protocol and procedures to maintain the integrity of the interior work area of the laminar air flow workstations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(17)">(17)</span> Written procedures as applicable for handling antineoplastic agents and other hazardous substances including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(17)(a)">(a)</span> Utilizing the proper equipment and supplies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(17)(b)">(b)</span> A statement that compounding shall be conducted within a properly certified biological safety cabinet or negative pressure compounding aseptic isolator;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(17)(c)">(c)</span> Proper use of protective attire; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(17)(d)">(d)</span> Proper techniques to prevent both contamination of the preparation and chemical exposure of the individual preparing the prescription;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(18)">(18)</span> Written procedures as applicable for the disposal of infectious materials or materials containing cytotoxic residues, or hazardous waste;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(19)">(19)</span> Written documentation of policy and procedure changes based on data gathered from quality assurance evaluations; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.12#C(20)">(20)</span> Written documentation of policies and procedures assuring the sterility and stability of compounded sterile preparations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.13" data-order="|10|34|19|.13|" data-ref-path="10|34|19|.13" class="h__section">.13 Attire.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A">A.</span> When compounding sterile preparations, individuals shall comply with the following standards:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(1)">(1)</span> Sequencing of garbing that complies with USP 797 Standards;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(2)">(2)</span> Thorough hand-washing before gowning;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(3)">(3)</span> Wearing clean room garb inside the designated area at all times, which consists of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(3)(a)">(a)</span> A non-shedding coverall or gown;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(3)(b)">(b)</span> Head and facial hair covers;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(3)(c)">(c)</span> A face mask; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(3)(d)">(d)</span> Shoe covers;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(4)">(4)</span> Clean room garb, with the exception of sterile gloves, shall be donned and removed outside the designated clean room area;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(5)">(5)</span> All jewelry shall be removed;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(6)">(6)</span> Sterile gloves are required; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#A(7)">(7)</span> Make-up may not be worn in the clean room.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.13#B">B.</span> The requirements of this regulation are not applicable if a compounding aseptic isolator is used to compound sterile preparations in accordance with USP 797 Standards and isolator vendor/manufacturer specifications.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.14" data-order="|10|34|19|.14|" data-ref-path="10|34|19|.14" class="h__section">.14 Training of Staff, Patient, and Caregiver.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#A">A.</span> The pharmacist shall make counseling available to the patient or primary caregiver, or both, concerning proper use of compounded sterile preparations and related supplies furnished by the pharmacy.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#B">B.</span> The permit holder shall ensure that pharmacy personnel engaging in compounding sterile preparations are trained and demonstrate competence in the safe handling and compounding of compounded sterile preparations and parenteral solutions, including cytotoxic agents if applicable.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#C">C.</span> The permit holder shall maintain records of training and demonstrated competence for individual employees for 5 years.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#D">D.</span> The permit holder shall ensure the continuing competence of pharmacy personnel engaged in compounding sterile preparations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E">E.</span> A pharmacy that compounds sterile preparations shall comply with the following training requirements:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)">(1)</span> The pharmacy shall establish and follow a written program of training and performance evaluation designed to ensure that individuals working in the designated area have the knowledge and skills necessary to perform the assigned tasks properly and include at least the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(a)">(a)</span> Aseptic technique with media fill verification at a frequency defined by risk level as described in USP 797 Standards:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(a)(i)">(i)</span> 12 months for low and medium risk; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(a)(ii)">(ii)</span> 6 months for high risk;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(b)">(b)</span> Pharmaceutical calculations and terminology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(c)">(c)</span> Compounding sterile preparation documentation process;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(d)">(d)</span> Quality assurance procedures;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(e)">(e)</span> Aseptic preparation procedures;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(f)">(f)</span> Proper cleansing, gowning, and gloving techniques;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(g)">(g)</span> General conduct in the controlled area;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(h)">(h)</span> Cleaning, sanitizing, and maintaining equipment used in the controlled area;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(i)">(i)</span> Sterilization techniques for high risk preparations; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(1)(j)">(j)</span> Container, equipment, and closure system selection.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(2)">(2)</span> Individuals assigned to the controlled area shall successfully complete practical skills training in aseptic technique and aseptic area practices.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(3)">(3)</span> Evaluations shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(3)(a)">(a)</span> Written testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(3)(b)">(b)</span> Observation for adherence to aseptic technique and aseptic area policies and procedures; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.19.14#E(3)(c)">(c)</span> Media fill verification as set forth in <a class="internal-link " href="/us/md/exec/comar/10.34.19.14#E(1)(a)" title="">§E(1)(a) of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.15" data-order="|10|34|19|.15|" data-ref-path="10|34|19|.15" class="h__section">.15 Quality Assurance.</h2>
                <p>The permit holder shall ensure that the compounded sterile preparation retains its potency and sterility throughout the assigned "beyond use" dating period through a written quality assurance program that includes:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#A">A.</span> A reasonable effort by the pharmacist to assure that compounded sterile preparations shall be kept under appropriate controlled conditions before dispensing, during transport, and at the location of use by providing adequate labeling and verbal or written instructions regarding proper storage and administration, as set forth by the product manufacturer and established standards and literature, with each compounded sterile preparation dispensed;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#B">B.</span> The phases of compounded sterile preparation, distribution, storage, administration, and directions for use for each type of preparation dispensed;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#C">C.</span> Environmental sampling for microbial organisms in laminar air flow workstations and clean rooms is performed according to methods and schedules specified by USP 797 Standards and if microbial contamination is suspected, for example, in the event of positive media fill verification results;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#D">D.</span> Laminar air flow workstations, biological safety cabinets, and compounding aseptic isolators certified by a trained and qualified operator;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#E">E.</span> Clean room and anteroom certification by a trained and qualified operator according to USP 797 Standards;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#F">F.</span> The proper disposal in accordance with accepted professional standards and applicable State and federal laws of unused drugs and materials used in the preparation of compounded sterile preparations, including antineoplastic agents and hazardous materials;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#G">G.</span> A formal written review process to report and evaluate compliance with this chapter; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.15#H">H.</span> A process that complies with applicable USP 797 Standards for performing sterility checks or pyrogen testing, or both, for applicable compounded sterile preparations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.16" data-order="|10|34|19|.16|" data-ref-path="10|34|19|.16" class="h__section">.16 Reference Library.</h2>
                <p>Minimum reference materials in a pharmacy shall include:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.16#A">A.</span> U.S. Pharmaceutical, General Chapter 797, Pharmaceutical Compounding — Sterile Preparations and other applicable reference materials in order to perform sterile compounding;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.16#B">B.</span> Reference materials containing drug stability and compatibility data; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.16#C">C.</span> Reference materials concerning drug interactions and incompatibility.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.17" data-order="|10|34|19|.17|" data-ref-path="10|34|19|.17" class="h__section">.17 Minimum Requirements for Inspections.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#A">A.</span> The Board shall inspect pharmacies located in Maryland at least annually.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#B">B.</span> The pharmacy shall provide as part of the inspection process:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#B(1)">(1)</span> Quality assurance testing reports;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#B(2)">(2)</span> Documentation of reporting adverse events as required in <a class="internal-link " href="/us/md/exec/comar/10.34.19.18" title=".18 Reporting Requirements Pharmacies.">Regulation .18 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#B(3)">(3)</span> Microbial testing of a sampling of the sterile compounded preparations of the pharmacy if applicable according to USP 797 Standards; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#B(4)">(4)</span> Any other information requested to ensure compliance with USP 797 Standards.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#C">C.</span> Within 90 days before the date of application, inspections of nonresident pharmacies may be conducted by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#C(1)">(1)</span> A designee of the Board;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#C(2)">(2)</span> The U.S. Food and Drug Administration; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#C(3)">(3)</span> Another appropriate state entity which indicates compliance with USP 797 Standards.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#D">D.</span> The Board or designee shall inspect nonresident pharmacies upon initial application and upon renewal.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#E">E.</span> The Board may inspect a pharmacy at any time to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#E(1)">(1)</span> Verify compliance with permit requirements; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.17#E(2)">(2)</span> Investigate a complaint.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.18" data-order="|10|34|19|.18|" data-ref-path="10|34|19|.18" class="h__section">.18 Reporting Requirements Pharmacies.</h2>
                <p>A pharmacy shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#A">A.</span> Document and perform routine testing as required by USP 797 Standards for the appropriate risk levels of sterile compounded preparations; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#B">B.</span> Report to the Board within 5 calendar days:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#B(1)">(1)</span> Adverse events that have been discovered including corrective actions taken or proposed;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#B(2)">(2)</span> Deficiencies related to the sterile compounding process;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#B(3)">(3)</span> Disciplinary actions in other states or by other state agencies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#B(4)">(4)</span> Changes in accreditation status;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#B(5)">(5)</span> Disciplinary actions taken against a pharmacist who is an owner, operator, or employee of the pharmacy; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.19.18#B(6)">(6)</span> Disciplinary actions taken against any other known permit, or any other authorization, held by the pharmacy permit holder.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.19.19" data-order="|10|34|19|.19|" data-ref-path="10|34|19|.19" class="h__section">.19 Office Use.</h2>
                <p>Unless otherwise authorized, a person that prepares and distributes sterile compounded medications for office use into, out of, or within the State shall hold:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.19#A">A.</span> A manufacturer’s permit or other permit designated by the U.S. Food and Drug Administration to ensure the safety of sterile compounded medications for office use; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.19.19#B">B.</span> If applicable, a wholesale distributor’s permit, issued by the Board under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 12, Subtitle 6C, Annotated Code of Maryland</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.34.18" aria-label="Chapter 18 Continuing Education for Pharmacists">
                <div class="h__ui">Previous</div>
                <span>Chapter 18 Continuing Education for Pharmacists</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.34.20" aria-label="Chapter 20 Format of Prescription Transmission">
                <div class="h__ui">Next</div>
                <span>Chapter 20 Format of Prescription Transmission</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
